Pompe disease is defined by acid alpha-glucosidase deficiency — and late-onset disease, ~70–80% of US patients, is where diagnostic delay and respiratory decline shape commercial strategy.
Pompe disease is an autosomal-recessive metabolic myopathy caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to glycogen accumulation in skeletal, respiratory, and (in infants) cardiac muscle. The US Pompe population is estimated at roughly 5,000–10,000 patients. Late-onset Pompe disease (LOPD), defined by residual GAA activity above about 1%, accounts for an estimated 70–80% of patients and spans a wide phenotype, from enzyme-test-detected and near-asymptomatic to wheelchair- and ventilator-dependent respiratory failure. Infantile-onset Pompe (IOPD), with near-absent GAA activity, presents in the first months of life with hypertrophic cardiomyopathy and profound hypotonia, and was historically fatal within the first year without treatment.
Two features define the LOPD landscape. First, diagnosis is slow: patients are frequently worked up for limb-girdle muscular dystrophy or idiopathic myopathy for years before a dried-blood-spot GAA enzyme assay confirms the diagnosis. Second, respiratory decline, not limb weakness, is the clinical clock; in the Pompe natural-history literature disease severity tracks disease duration, so earlier-onset patients reach wheelchair and ventilator dependence sooner. Newborn screening for Pompe is expanding the pre-symptomatic identified pool and reshaping when and where enzyme replacement therapy begins.
Late-onset versus infantile-onset Pompe disease — clinical and diagnostic comparison
| Parameter | Late-Onset Pompe (LOPD) | Infantile-Onset Pompe (IOPD) |
|---|---|---|
| Share of US Pompe | ~70–80% of patients | ~20–30% of patients |
| Residual GAA activity | Partial (>~1%) | Near-absent (<1%) |
| Typical onset | Childhood to late adulthood | First months of life |
| Cardinal features | Proximal limb-girdle weakness; progressive respiratory / diaphragmatic decline | Hypertrophic cardiomyopathy; profound hypotonia; respiratory failure |
| Diagnostic test | Dried-blood-spot GAA assay → confirmatory GAA gene sequencing | Same; frequently flagged first by newborn screening |
| Newborn screening | Shifts detection pre-symptomatic; surveillance until symptom onset | Enables early ERT before irreversible cardiac damage |
| Natural history | Progressive; severity tracks disease duration; ventilator/wheelchair dependence over time | Rapid; historically fatal within the first year untreated |
Sources: Kishnani PS et al. Genet Med 2006 (PMID 16702877); Hagemans ML et al. Neurology 2005 (PMID 15985590); van der Ploeg AT & Reuser AJJ. Lancet 2008 (PMID 18929906); AMDA / NORD Pompe epidemiology.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- US Pompe prevalence estimate
- the LOPD versus IOPD split by residual GAA activity
- the phenotype spectrum from enzyme-test-detected to ventilator-dependent
Delivers
- The limb-girdle-muscular-dystrophy misdiagnosis pathway
- the dried-blood-spot GAA assay as the definitive test
- newborn screening's role in pre-symptomatic identification
Delivers
- Respiratory decline as the clinical clock
- severity tracking disease duration in the Pompe natural-history literature
- the functional measures (FVC and 6-minute walk) that gate treatment
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why GAA enzyme deficiency below roughly 1% residual activity separates infantile-onset from late-onset Pompe disease.
- How glycogen accumulation in skeletal, respiratory, and cardiac muscle drives the disease's two distinct phenotypes.
- Why LOPD accounts for 70-80% of the estimated 5,000-10,000 US Pompe patients, per AMDA and NORD.
- How residual GAA activity above 1% defines LOPD versus the near-absent activity that marks IOPD.
- Why LOPD patients are frequently misdiagnosed with limb-girdle muscular dystrophy for years before confirmation.
- How the dried-blood-spot GAA assay, followed by gene sequencing, closes the diagnostic gap identified by Kishnani 2006.
- Why respiratory decline, not limb weakness, is the clinical clock that determines treatment timing in LOPD.
- How disease severity tracking disease duration means earlier-onset patients reach ventilator dependence sooner.
- Why newborn screening is expanding the pre-symptomatic identified pool and reshaping when enzyme replacement therapy begins.
- How early detection in IOPD enables enzyme replacement therapy before irreversible cardiac damage occurs.
- Why LOPD spans a spectrum from enzyme-test-detected, near-asymptomatic patients to wheelchair- and ventilator-dependent cases.
- How IOPD's hypertrophic cardiomyopathy and profound hypotonia within months of birth contrast with LOPD's decades-long course.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Pompe disease landscape is built from primary epidemiological sources, peer-reviewed clinical literature, and registry data. Epidemiological estimates are triangulated across multiple sources; all figures carry source citations.
Key sources: Kishnani PS et al. Genet Med 2006 (PMID 16702877); Hagemans ML et al. Neurology 2005 (PMID 15985590); van der Ploeg AT & Reuser AJJ. Lancet 2008 (PMID 18929906); AMDA and NORD Pompe disease epidemiology references.
- Pompe diagnosis pathway and phenotype classification verified against Kishnani PS et al. Genet Med 2006 (PMID 16702877)
- LOPD natural history (severity tracking disease duration) verified against Hagemans ML et al. Neurology 2005 (PMID 15985590)
- Disease biology and ERT context verified against van der Ploeg AT & Reuser AJJ. Lancet 2008 (PMID 18929906)
- US prevalence and the LOPD/IOPD split triangulated against AMDA and NORD Pompe disease references
Frequently asked questions
Commission this assessment
AXLRx Pompe Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US late-onset Pompe population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.